Cornelia Haag-Molkenteller biography
Dr. Cornelia Haag-Molkenteller M.D., Ph.D. is the Chief Medical Officer of USI, a subsidiary of the Company. From April 2015 to March 2018, Dr. Haag-Molkenteller was the Vice President in Clinical Development at Allergan plc, and from November 2007 to March 2015, the Vice President in Global Drug Development. While at Allergan, she led clinical development of onabotulinumtoxinA (BOTOX) for OAB and neurogenic detrusor overactivity. From 1988 to 2006, she was the Vice President of Clinical Program Leadership at Schwarz Biosciences GmbH. Dr. Haag-Molkenteller earned an M.D. and Ph.D. from Johann Wolfgang Goethe-Universität Frankfurt am Main.
What is the salary of Cornelia Molkenteller?
As the Chief Medical Officer of USI of Urovant Sciences Ltd, the total compensation of Cornelia Molkenteller at Urovant Sciences Ltd is 1,703,470$. There are no executives at Urovant Sciences Ltd getting paid more.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Cornelia Molkenteller?
Cornelia Molkenteller is 61, he's been the Chief Medical Officer of USI of Urovant Sciences Ltd since 2018. There are no older and 6 younger executives at Urovant Sciences Ltd.
What's Cornelia Molkenteller's mailing address?
Cornelia's mailing address filed with the SEC is C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE, CA, 92617.
Insiders trading at Urovant Sciences Ltd
Over the last 6 years, insiders at Urovant Sciences Ltd have traded over 0$ worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth 411,146,115$ . The most active insiders traders include Sciences Ltd. Roivant、Global Investors Lp Viking ...、Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of 6,293,420$. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth 1,350,510$.
What does Urovant Sciences Ltd's logo look like?
Urovant Sciences Ltd executives and stock owners
Urovant Sciences Ltd executives and other stock owners filed with the SEC include:
-
Cornelia Haag-Molkenteller,
Chief Medical Officer of USI -
Bryan Smith,
General Counsel - USI -
Michael McFadden,
Chief Commercial Officer -
Christine Ocampo,
Senior Vice President, Chief Accounting Officer, Principal Accounting Officer -
Kenton Stewart,
Senior Vice President of Market Access -
Walt Johnston,
Senior Vice President of Commercial -
James Hindman,
Director -
Shigeyuki Nishinaka,
Director -
Ajay Bansal,
Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer -
Myrtle Potter,
Chairman of the Board -
James Robinson,
Principal Executive Officer, Director -
Pierre Legault,
Independent Director -
Sef Kurstjens,
Independent Director -
Holdings Ltd.Dexcel Pharma ...,
-
Associates Gp Llcqvt Fund V...,
-
Patrick Machado,
-
Frank Torti,
Director -
Global Investors Lp Viking ...,
-
Investments (Uk) Ltd Soft B...,
-
Nori Ebersole,
SVP&CHRO-Urovant Sciences,Inc. -
Global Performance Llc Viki...,
-
Sciences Ltd. Roivant,
10% owner -
Andrew Lo,
-
Global Performance Llc Viki...,
-
Associates Gp Llcqvt Financ...,
-
Chemical Co., Ltd.Sumitomo ...,
-
Keith Katkin,
PEO;CEO/Urovant Sciences, Inc.